top of page

Enanta’s CEO discusses RSV and Covid drug development on its earnings day

Jay Luly goes in depth on antiviral drug development and discusses his company’s efforts to try to develop the first therapeutic for RSV.



Opmerkingen


Join the BiotechTV mailing list

Thanks for subscribing!

bottom of page